• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

303
75
51
51
35

COUNTRY

34
13
13
12
12

PRICE

757
911
1,219
1,695

PUBLISHED

21
43
320
1,695

PRODUCT TYPE

1,093
499
85
16
2

Infectious Diseases

Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed under Research and Markets’ Infectious Diseases category.

Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.

For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices. Show Less
Read more

PRODUCT TITLE

Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update

PharmaPoint: Seasonal Influenza Vaccines - Global Drug Forecast and Market Analysis to 2022: Event-Driven Update Summary Seasonal Influenza is a respiratory infection caused by influenza virus that...

September 2013
FROM

Warts Global Clinical Trials Review, H2, 2013

Warts Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Warts Global Clinical Trials Review, H2, 2013" provides data on the Warts clinical trial scenario. This report provides...

September 2013
FROM

PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022

PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast...

September 2013
FROM

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

Menactra (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Menactra (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022

PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - Australia Drug...

September 2013
FROM

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

NeisVac-C (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Menitorix (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Menveo (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset...

September 2013
FROM

Influenza Global Clinical Trials Review, H2, 2013

Influenza Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Influenza Global Clinical Trials Review, H2, 2013" provides data on the Influenza clinical trial scenario. This...

September 2013
FROM

Sepsis Global Clinical Trials Review, H2, 2013

Sepsis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Sepsis Global Clinical Trials Review, H2, 2013" provides data on the Sepsis clinical trial scenario This report provides...

September 2013
FROM

Schistosomiasis Global Clinical Trials Review, H2, 2013

Schistosomiasis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Schistosomiasis Global Clinical Trials Review, H2, 2013" provides data on the Schistosomiasis clinical trial...

September 2013
FROM

Dengue Global Clinical Trials Review, H2, 2013

Dengue Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Dengue Global Clinical Trials Review, H2, 2013" provides data on the Dengue clinical trial scenario. This report...

September 2013
FROM

Menjugate (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Menjugate (Meningococcal Vaccines) - Forecast and Market Analysis to 2022 Summary Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid...

September 2013
FROM

PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022

PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Meningococcal Vaccines - France Drug Forecast...

September 2013
FROM
Antibody Fc: Antibody Fc: - Product Thumbnail Image

Antibody Fc:

Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance...

September 2013

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013

Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Mycobacterium Tuberculosis Infections - Pipeline Review, H2 2013', provides an overview of the indication’s...

September 2013
FROM

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013

Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Leishmaniasis (Kala-Azar) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

Human Papillomavirus Infections - Pipeline Review, H2 2013

Human Papillomavirus Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Human Papillomavirus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM
Loading Indicator

Our Clients

Our clients' logos